According to Flush statistics, up to 12:00 on January 18, 2018, out of 284 A-share pharmaceutical bioprocessing companies, 118 have released their 2017 performance forecasts.
Among them, 57 were pre-increased, 13 were pre-paid, 3 were pre-lost, 4 were pre-paid, 3 were loss-making and 4 were declined sharply, with a sharp rise of 30 and uncertainties 4.
From the forecasted net profit changes, Berry is expected to have the highest increase, with a net profit forecast of 5,547.06% in 2017. In addition, Yabao Pharmaceutical (803%) is expected to have net profit up 100% , Livzon Group (460.8%), Yisheng Pharmaceutical (375%), Joincare (373.22%), Yongan Pharmaceutical (185%), Tiger medicine (114.95%), Thai joint health (112.13%), Shuangcheng Pharmaceutical (102.57%) and other eight.
Watson Biologicals, Ji'an Medical and Bohui Innovations are the three pre-losing companies in the 118 listed pharmaceutical companies that have released their performance forecasts, of which Walson Bio and Ji'an Medical Net profit were -860.72% and -1065.66 respectively %.
In addition, Livzon Group (4.339 billion yuan), Health yuan (2.136 billion yuan), Xinhecheng (1.624 billion yuan), Shanghai Lai Shi (1.613 billion yuan) currently forecasted to have a net profit of over 1 billion yuan in 2017, Li Tai (1,466,000,000 yuan), billion fan medicine (1,269,000,000 yuan).
